SARS-CoV-2 Spike RBD Neutralizing Antibody, monoclonal

SKU: orb1274211

Description

Images & Validation

−

Item 1 of 7

Tested Applications	ELISA, WB
Reactivity	Human

Key Properties

−

Antibody Type	Primary Antibody
Clonality	Recombinant
Isotype	Human IgG1/kappa
Immunogen	Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 ug/mL using SARS-CoV-2 Inhibitor Screening Kit .Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
Target	S
Purification	>95% as determined by SDS-PAGE.
Conjugation	Unconjugated

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Form/Appearance	Lyophilized
Buffer/Preservatives	Lyophilized from 0.22 Î¼m filtered solution in PBS, pH 7.4 . Normally trehalose is added as protectant before lyophilization.
Concentration	batch dependent
Disclaimer	For research use only

Alternative Names

−

spike glycoprotein

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

SARS-CoV-2 Spike RBD Neutralizing Antibody, monoclonal

Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by SARS-CoV-2 Inhibitor screening Kit with a half maximal inhibitory concentration (IC50) of 1.472 ug/mL (QC tested).

Immobilized SARS-CoV-2 S1 protein, His Tag at 2 ug/mL (100 uL/well) can bind Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 with a linear range of 0.2-1.95 ng/mL (QC tested).

Serial dilutions of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1 was detected by Anti-SARS-CoV-2 Neutralizing Antibody Titer Serologic Assay Kit with a half maximal inhibitory concentration (IC50) of 0.6265 ug/mL (Routinely tested).

Serial dilutions of Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody was incubated with SARS-CoV-2 pseudotyped virus at 37C for 1 hour. Afterward, Huh-7 cells were added, followed by incubation at 37C for 24h. Chemiluminescence detection was performed and the virus neutralization titers (IC50) is 2.181 nM using the Reed-Muench method.

FACS analysis shows that the binding of SARS-CoV-2 S protein RBD, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S protein RBD used is 5 ug/ml. The IC50 is 10.33 ug/ml (Routinely tested).

FACS analysis shows that the binding of SARS-CoV-2 S1 protein, Mouse IgG2a Fc Tag to Vero E6 cells surface ACE2 was inhibited by increasing concentration of Anti-SARS-CoV-2 RBD Neutralizing Antibody, Human IgG1. The concentration of SARS-CoV-2 S1 protein used is 3 ug/ml. The IC50 is 1.352 ug/ml (Routinely tested).

Quick Database Links

Gene Symbol

UniProt

P0DTC2

UniProt Details

−

No UniProt data available

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

Western Blot (IB, immunoblot)

View Protocol

ELISA

Enzyme-linked Immunosorbent Assay (EIA)

View Protocol

Find More Protocols